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Abstract
The accuracy of dose calculation algorithms has been a topic of interest among the radiotherapy community throughout last
decades. On one hand the advancements in computers and algorithms has improved the accuracy, but on the other hand the
developments in other parts of treatment process, in treatment delivery techniques and in treatment devices have always
pushed the requirements to the next level. In this review article a comprehensive overview on the accuracy of a new type ‘c’
dose calculation algorithm, the Acuros XB (AXB) algorithm (Varian Medical Systems, Inc., Palo Alto, CA, USA), is provided. All
the articles that have applied the AXB algorithm in terms of external beam radiotherapy are included and the research frames
with reported deviations to reference methods are described. For the homogeneous water phantoms the reported accuracy was
from 1% to 2%, being of similar level for heterogeneous phantoms, in rare occasions lower. In anthropometric and anthropo-
morphic phantoms the mean deviations were about 2% and slightly larger for single points and/or small regions. With patient
plans the reported average discrepancies were less than from 3% to 5%. Almost without exceptions, the algorithm has proven to
perform better than other existing commercial dose calculation algorithms. The number of such papers, in which the AXB algo-
rithm is the only dose determination method, is already notable, which indicates that the accuracy of the algorithm is trusted
for reference use and it also, with reported dosimetric results, implies that the AXB algorithm has reached its maturity.
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Introduction
The significance of dose calculation accuracy in the radio-
therapy delivery process has increased during past decades.
The introduction of CT images in radiotherapy allowed the
inclusion of detailed anatomical geometry and material in-
formation in dose calculations. However, clinical dose calcu-
lation algorithms relied for a long time to the measurements
in water and simplified corrections for patient contour and
heterogeneities. These so called correction-based algorithms,
also known as type ‘a’ algorithms are nowadays mostly re-
placed by type ‘b’ algorithms that are model-based to a vary-
ing degree, using superposition and convolution techniques.
Type ‘b’ algorithms have provided increased accuracy over
type ‘a’ algorithms in majority of clinical situations, but in the
extreme ends of the density range of biological tissues (e.g.,
air, lung and bone) and in high-Z implanted materials (here,
high-Z materials are regarded as materials with larger mass
density than found in human tissues), they have been shown
to produce clinically unacceptable discrepancies, when
comparing to reference methods. In the Report 85 from Task
Group 65 of American Association of Physicists in Medicine
(AAPM)1 the importance of the dose calculation accuracy was
demonstrated by determining the proportion of each source
of uncertainty in the whole radiotherapy treatment process.
At that time (year 2004) the accuracy was estimated to range
from 1.0% to 5.0%, but to decrease below 3.0% in the future.
However, while other sources of uncertainty were estimated
to decrease as well, the relative contribution of the dose cal-
culation accuracy was to increase. During past decade the
developments in radiotherapy have taken place in treatment
delivery, in the form of intensity modulated radiotherapy
(IMRT) and volumetric modulated arc radiotherapy (VMAT),
which use treatment fields applying small field segments
generated by multi-leaf collimators (MLC), and in treatment
protocols, which favor hypofractionation, i.e., large treat-
ment doses per fraction delivered to small target volumes.
These advancements have also posed a demand for more
accurate dose calculation, which has been realized as a new
generation of algorithms that are based on fast Monte Carlo
(MC) methods or so called grid-based linear Boltzmann
transport equation (LBTE) solvers. Characteristic for the most
recent class of algorithms, type ‘c’, is that 1) the modelling of
secondary electron transport has been developed to next
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level, when comparing to type ‘a’ and ‘b’ algorithms, 2) they
are able to calculate the dose deposition, in addition to all
biological tissues, also in the presence of high-Z implanted
materials and 3) the dose is reported as dose to medium2, 3.
The first addition to this group of algorithms and the only
commercial grid-based LBTE solver for radiotherapy pur-
poses is the Acuros XB (AXB) algorithm implemented in the
Eclipse treatment planning system (TPS) by Varian Medical
Systems, Inc. (VMS) (Palo Alto, CA, USA).4 Originally, the
roots of the AXB algorithm lie in the Attila LBTE solver de-
veloped and benchmarked by a group based on the founders
of the Transpire, Inc. (Gig Harbor, WA, USA).5, 6, 7, 8 The
original Acuros LBTE solver designed for radiotherapy dose
calculations was developed by Transpire, Inc. from the At-
tila9, which was then implemented as the AXB algorithm in
the Eclipse TPS4. The AXB algorithm was developed to ad-
dress the clinical needs of dose calculation accuracy compa-
rable to full MC methods with moderate calculation times,
especially with treatment plans with large number of field
segments, such as in VMAT. The BTE is a coupled system of
integrodifferential equations that describe the transport and
interactions of various particles (photons, electrons, neutrons,
etc.) in matter in macroscopic level. When expressed in lin-
earized form it is assumed that the transport of each particle is
independent of other transported particles and no electro-
magnetic fields are present. As analytical, closed form solu-
tions for LBTE in calculation geometries typically applied in
radiotherapy are not known, non-analytical, open form solu-
tions must be applied. With grid-based LBTE solvers the
solution is achieved with numerical methods, with which in
ideal case the solution would only contain the error produced
by the uncertainties in the particle interaction data. However,
the core idea with the grid-based LBTE solvers is to discretize
the variables in space, angle and energy, which generates
systematic error and the total, combined uncertainty from
abovementioned sources is defined by the compromise be-
tween the level of discretization and desired calculation
speed. In addition, a small uncertainty is generated, since the
AXB algorithm, similar to MC algorithms, employs energy
cutoff values for photon and electron transport, which means
that the particle transport is terminated and energy is ab-
sorbed locally, when the energy of a particle falls below the
set cutoff values.4
The radiotherapy treatment plan dose calculation with the
AXB algorithm can be divided in two phases. In the first
phase the radiation beam propagation in the linear accelera-
tor treatment head is simulated. The AXB algorithm uses the
same sub-source models as implemented in the Analytic,
Anisotropic Algorithm (AAA), i.e., the model contains sub
sources for: 1) primary photons, which are generated in the
X-ray target, but not interacted elsewhere in the treatment
head, 2) extra-focal photons, which are generated in interac-
tions in other treatment head components, and 3) electron
contamination, which represents the electrons generated in
the treatment head components and in the air.10, 11, 12, 13, 14,15
The radiation beam fluence determined by the source model,
modulated by the plan-specific jaw and MLC configurations,
is then directed to the patient, which is the first step in the
second phase of the dose calculation. In the patient dose
calculation, the following steps are performed: 1) transport of
source model fluence into the patient, 2) calculation of scat-
tered photon fluence in the patient, 3) calculation of scattered
electron fluence in the patient, and 4) dose calculation. Step
1) is repeated for each field direction and steps 2) to 3) are
performed only once for each patient geometry voxel. In the
final step 4) the absolute dose in each voxel is calculated using
the determined electron angular fluence, macroscopic elec-
tron energy deposition cross sections and material density of
the voxel.4, 9 Since the AXB algorithm performs explicit sim-
ulation of physical interactions in matter, the material map-
ping needs to be done for the CT-based patient geometry
prior to abovementioned steps. Mass density and material
type are defined for each voxel in the material mapping,
applying CT simulator specific CT number to mass density
conversion curve and material library provided with the AXB
algorithm. The material library includes five tissue types and
16 other materials, the mass density upper limit being 8.0 g/cc
for stainless steel.4 Thus, the report mode for the final dose
distribution is referred to as dose-to-medium in medium
(Dm,m). Although the AXB algorithm inherently calculates
Dm,m, the dose distributions can be converted to
dose-to-water in medium (Dw,m), which is done by replacing
the medium-based fluence-to-dose response function used in
absorbed dose calculation with a water-based response func-
tion. In the type ‘a’ algorithm implemented in Eclipse TPS,
the pencil beam convolution (PBC) algorithm and in the
AAA, which is a type ‘b’ algorithm, the dose report mode is
also Dw,m, but in those algorithms the dose results are based on
electron density-based corrections applied to dose kernels
calculated in water.4, 9, 16 Therefore Dw,m mode of the AXB
algorithm represents more closely true absorbed dose to wa-
ter.17
A more rigorous and detailed description of the AXB algo-
rithm is provided in the white paper from VMS by Failla
et al.4 and in the first papers benchmarking the accuracy of
the original Acuros algorithm9 and the AXB algorithm17, 18.
Kan et al.19 have provided a review article on grid-based LBTE
solvers (i.e., the AXB algorithm), which presents the results of
selected earlier papers describing the validation of the AXB
algorithm for clinical use. The purpose of this review article is
to present all the papers to date (Sep 2014) in which the AXB
algorithm has been benchmarked, but also to cover such
papers, where the dose distributions are solely produced by
the AXB algorithm. To include all the articles implementing
the AXB algorithm, the literature search was performed using
PubMed and Scopus databases, but also a search was con-
ducted at the website of each relevant journal, in order to
include also those journals that are not included in the data-
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bases. Separate searches for keywords ‘Acuros’ and ‘AXB’
were performed in each case. The information on different
dose calculation algorithms and measurements is included, as
is the information on the research frame, e.g., what kinds of
phantoms were used, what was the underlying clinical con-
text of the work. The results between the AXB algorithm and
the reported reference method (or assumed by the author of
this article) are presented, but due to the limited space, for the
results for other algorithms the reader is encouraged to con-
sult the original paper. The presented AXB calculation results
are in Dm,m.
The AXB algorithm and homogeneous phantoms
The benchmarking in a homogeneous phantom is the first
step in the validation process of a new dose calculation algo-
rithm. Therefore, for new algorithms on the market, such as
the AXB algorithm, it has been done in the most of the first
publications that have included the algorithm. A
pre-requisite for this is that the reference dose determination
method, being a measurement and/or other dose calculation
algorithm, has to be able to provide accurate, reference results
with small uncertainty in the calculation geometry that is
studied. Since all dose determination methods include an
inherent uncertainty, the extent of this error needs to be
known for accuracy assessment of the AXB algorithm.
The first validation of the AXB algorithm (versions 10 and 11)
in homogeneous water phantom was presented by Fogliata et
al.18 For 6 and 15 MV flattened beams and 6 and 10 MV flat-
tening filter free (FFF) beams for field sizes (FSs) ranging from
2 × 2 to 40 × 40 cm2 the reported uncertainties were within
1% for open beams and 2% for beams with mechanical
wedges, when compared with measurements and the AAA.
Full MC algorithms, such as EGSnrc/BEAMnrc/DOSXYZnrc,
Geant, Penelope and MCNP, when appropriately commis-
sioned, are considered to represent the most accurate means
to determine dose distributions, especially in complex 3D
phantoms including heterogeneities.20 In a study by Bush et
al.17 the AXB algorithm version 10 (the AXB10) was bench-
marked for 6 and 18 MV beams against full MC simulations,
measurements and the AAA. For FSs ranging from 4 × 4 to 30
× 30 cm2 in regions excluding large dose gradients the dis-
crepancies were within ±2%, usually much less, between all
the methods. Similar findings are presented for the AXB10 in
paper by Han et al.16, where also type ‘b’ collapsed-cone
convolution (CCC) algorithm implemented in Pinnacle 9.0
TPS (Philips Medical Systems, Cleveland, Inc., Fitchburg, WI,
USA) was included. In a study by Hoffmann et al.21 prior to
clinical implementation the AXB10 was benchmarked for 6
and 15 MV beams against output factor (OF), percentage
depth dose (PDD) and profile measurements and the corre-
sponding AAA calculations. Results for output factors against
measurements were within 1%, 1% and 1 mm distance to
agreement (DTA) for PDDs and 2%/1 mm in profiles ex-
cluding penumbrae. Mißlbeck and Kneschaurek22 compared
the AXB10 to the AAA and XVMC fast MC algorithm im-
plemented in iPlan TPS (BrainLab AG, Feldkirchen, Germa-
ny), qualitatively stating that there were no large differences
in PDDs for 10 x 10 cm2 field with 6 and 15 MV beams.
The trend in recent past in radiotherapy has been to treat
small tumors with conformal static MLC-shaped fields, ap-
plying hypofractionation, i.e., using high dose fractions in-
stead of conventional fractionation schemes. At present, these
so called stereotactic body radiotherapy (SBRT) and stereo-
tactic radiosurgery (SRS) treatments are delivered with IMRT
and VMAT techniques, which use even smaller MLC-shaped
apertures than in treatments with static MLC-shaped fields.
All this has increased the importance of the dose calculation
accuracy in small field apertures, especially because with
smaller number of treatment fractions the relative im-
portance of each fraction increases correspondingly. To ad-
dress this, there are several papers that concentrate on the
accuracy of the AXB algorithm with small fields and follow-
ing issues. Fogliata et al.23 benchmarked the accuracy of the
AXB11 and the AAA against measurements with static
jaw-collimated 6 MV fields ranging from 0.8 × 0.8 to 3 × 3 cm2
and several VMAT fields with varying jaw-collimation. The
accuracy of the AXB11 was within 0.2% and gamma agree-
ment index (GAI) values higher than 95% were achieved for
FSs larger than 1 × 1 cm2. For smaller fields the discrepancies
were larger. A white paper from VMS by Torsti et al.24 as-
sessed the dose calculation accuracy of the AAA, the AXB10
and the AXB11 with small MLC-delimited fields, presenting
also the influence of several parameters included in algorithm
configuration and dose calculation options. With 2%/1 mm
GAI acceptance criteria the calculation results against meas-
urements were good for all field configurations excluding the
field with 1 × 1 cm2 MLC-collimation and 2 × 2 cm2
jaw-collimation. The effect of the air cavity correction option
in Eclipse VMAT optimization engine was tested by Kan et
al.25 and the final VMAT plan dose calculation was performed
with the AXB10 and the AAA. In water phantom the AAA
resulted in slightly higher dose coverage in planning target
volume (PTV) and near-maximum dose in organ-at-risk
(OAR).
Whenever there are MLC-delimited static or dynamic fields,
there is dose contribution due to the jaw and MLC transmis-
sion and interleaf gap leakage radiation. Kron et al.26 and
Fogliata et al.27 assessed the accuracy of the AXB11 and the
AAA under the shielding by the jaw, the MLC or the both
with varying static and VMAT fields. In general, good results
were obtained for both algorithms, the largest discrepancies
being for the smallest fields. In this context, the effect of the
value of an AXB algorithm configuration parameter (also
present in the AAA) called ‘effective spot size’, in addition to
MLC parameters (transmission and dosimetric leaf gap), was
highlighted and the tuning of the parameter is also discussed
in Torsti et al.24. Additionally, there are two other studies,
where the AXB algorithm has been used in conjunction with
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homogeneous water phantoms. In work by Tan et al.28 the
AXB10 was compared with the PBC algorithm and the AAA
implemented in Eclipse TPS and FFT convolution algorithm
and multigrid superposition algorithm implemented in XiO
TPS (Elekta AB, Stockholm, Sweden) and VMC fast MC al-
gorithm implemented in Monaco TPS (Elekta AB). The algo-
rithms were used to determine the entrance and exit doses to
be used in in vivo dosimetry. In comparison to point dose
measurements, the AXB10, XiO algorithms and Monaco
produced deviations of 2 - 3%, whereas the deviations for the
PBC algorithm and the AAA were about 5%. In profile and
2D comparison the VMC algorithm performed better than
the AXB10. Jeevanandam et al.29 applied the AXB11 with the
AAA for benchmarking the in-house independent monitor
unit verification calculation for VMAT. The AXB11 was
compared with total scatter factor and tissue maximum ratio
measurements, with mean deviations of 0.83% and -0.15%,
respectively. However, the further results in the study reveal
that the improved accuracy of the AXB11 produces larger
differences between the in-house dose calculation program
and the AXB11 than compared to the AAA.
The AXB algorithm and heterogeneous phantoms
The second step in validation process of a new dose calcula-
tion algorithm is to assess the accuracy of the algorithm in
heterogeneous phantoms, i.e., phantoms that contain differ-
ent materials. The structure of the phantom may consist of
slabs or layers of various materials, which are perpendicular
to beam axis. In this case the accuracy of the heterogeneity
correction of the dose calculation engine is tested mainly in
forward direction. When including heterogeneities of dif-
ferent size and shapes in various locations in the phantom,
the performance of the heterogeneity correction is also
benchmarked in lateral directions. This way the phantom
may also represent better anatomical geometries and by
choosing tissue-equivalent materials to the phantom, the
results are more effectively transferable to clinical setting.
In the report by Vassiliev et al.9 the predecessor of the AXB
algorithm, Acuros algorithm by the Transpire Inc. was com-
pared in heterogeneous phantom against full MC simulations
for 6 and 18 MV beams with FSs ranging from 2.5 × 2.5 cm2 to
10 × 10 cm2. The phantom, so called ‘ICCR benchmark’30,
consisted of slabs of water, bone and lung. The maximum
differences were 1.2% and 2.3% for 6 and 18 MV beams,
respectively. For 18 MV beam the largest difference was for
the smallest FS – for all other fields the maximum difference
was 1.1%. In profiles the differences were of similar order and
the DTA values were less than 1 mm. In the white paper by
Failla et al.4 the AXB algorithm was shown to have very good
visual agreement with full MC simulations in slab phantoms
containing various materials from the AXB algorithm mate-
rial library. Bush et al.17 studied the performance of the
AXB10 against full MC calculations and the AAA with 6 and
18 MV beams and several FSs in unit-density phantoms con-
taining air or lung with varying density and bone represent-
ing ribs. The deviations between the AXB10 and full MC
simulations were within ±2 - 3% for the phantoms with lung
and ±1.5 - 4.5% for the phantom with air, with only very
small regions of larger discrepancies, usually occurring at the
interface between the lung/air and tissue parallel to the beam.
The results for the phantom containing lung were
cross-checked against measurements with similar findings by
Kroon et al.31 In the work by Han et al.16 the AXB10 was
compared to the AAA, the CCC algorithm implemented in
Pinnacle TPS and full MC simulations for 6 and 18 MV beams
in multilayer slab phantom containing soft tissue, bone and
lung. The average differences for the AXB10, when compared
to the full MC simulations, were 1.1%, which was better than
with other algorithms. Similar results were achieved by
Fogliata et al.32, who compared the AXB10 and the AXB11
against VMC++ fast MC algorithm and the AAA in phantoms
containing air, lung of varying density, adipose, skeletal
muscle, cartilage and bone. With 3%/3 mm acceptance crite-
ria the GAI values in comparison to VMC++ algorithm were
100% for lung with normal density and bone and 86% for
light lung. In the paper by Mißlbeck and Kneschaurek22 the
AXB10 was compared to the AAA and XVMC fast MC algo-
rithm in iPlan TPS in water phantoms containing lung and
bone. The calculated dose distributions showed only minor
differences between the AXB10 and XVMC algorithm. The
AXB11, the AAA and the XVMC algorithm were also
benchmarked in a study by Tsuruta et al.33, accompanied with
measurements. The deviations between the AXB11 and
measurements were generally within ±3%, the maximum
difference being -5.5%. Notable was that it was one of the
rare studies, where other TPS algorithm, the XVMC in this
case, achieved more accurate results than the AXB algorithm,
when comparing to the reference method. Stathakis et al.34
assessed the accuracy of the AXB10 with small fields (1 × 1 - 5
× 5 cm2) in water phantoms containing lung, bone or air
inserts for 6 MV beams by comparing to full MC simulations
and the AAA and the CCC algorithm implemented in Pinna-
cle TPS. The agreement between the AXB10 and full MC
simulations was within 2% for lung and bone, but for the
phantom with air, the deviations were larger – ranging from 3
to 15%. In study by Kan et al.25, which tested the effect of the
air cavity correction option in Eclipse VMAT optimization
engine, calculations were also performed in heterogeneous
phantoms. The improved accuracy of the AXB10 compared to
the AAA resulted to that in the AXB10 dose distributions the
PTV dose coverage was much lower and therefore the choice
of the algorithm affects the subsequent results of the study.
However, the final impact on patient treatment planning was
not fully revealed by the study.
There are a couple of groups that have applied similar type of
heterogeneous phantoms in several papers. In studies by Kan
et al.35, 36, 37, where the accuracy of the AXB10 for the naso-
pharyngeal carcinoma (NPC) treatment planning has been
assessed, a rectangular phantom of variable size with variable
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size rectangular air cavity or bone insert in the middle and
rod-type bone inserts on both sides of the air cavity has been
used. The comparison has been done against measurements,
full MC simulations and the AAA. The congruence of the
AXB10 with the reference methods, where available, was
generally good, maximum differences near air/tissue inter-
faces being 6% and the GAI value with 3%/3 mm acceptance
criteria being only once less than 96%. Rana et al.38, 39, 40, 41
have benchmarked the accuracy of the AXB10 and the AAA
with 6 MV beams mainly for lung SBRT and radiotherapy of
esophageal cancer in heterogeneous slab phantoms contain-
ing solid water and air gap, with additional lung insert in one
study41. When comparing to measurements, the largest dis-
crepancies for the AXB10 were -3.9% near the air/water
interface40, while the ranges for deviations were within
±0.5%39, from -3.8% to 0.9%38, from -3.9% to -0.4%40 and
from -1.7% to 2.8%41.
The accuracy of dose calculation algorithms in the presence
of high-Z materials has been a challenge during past decades
to the extent that it is general to avoid such beam directions
from which the beam would primarily traverse through
high-Z material, e.g., hip implants. Of course this is not al-
ways possible, e.g., in the case of dental implants, and along-
side with the improvements in metal artifact removal (MAR)
techniques, there is also a need for more accurate dose cal-
culation. Some of the most advanced dose calculation algo-
rithms to date are able to predict the beam attenuation in
high-Z material to some extent, but none of them are able to
model the backscatter peak in dose at the tissue/high-Z ma-
terial interface. In the work by Failla et al.4 it was shown that
the AXB algorithm is able to calculate the dose distribution in
the presence of high-Z materials, such as aluminum, titanium
alloy and stainless steel, when compared to full MC simula-
tions. Lloyd and Ansbacher42 assessed the accuracy of the
AXB11 against measurements, full MC simulations and the
AAA in a cubic water phantom with stainless steel and tita-
nium alloy inserts. There is a visual agreement with the
measurements and both the full MC simulations and the
AXB11. For the 6 and 18 MV beams GAI values of 96.8% and
91.3% were achieved between the full MC simulation and the
AXB11, with acceptance criteria of 2%/1 mm.
The AXB algorithm and anthropometric/anthropomorphic
phantoms
In the validation process of a new dose calculation algorithm
the third step is the utilization of anthropometric phantoms,
which mimic the anatomy of a patient, and anthropomorphic
phantoms, which in addition to mimicking the anatomy, also
make use of the tissue-equivalent materials. These phantoms
represent the most complex types of phantoms, in which
reference measurements may be performed (excluding the
rare cases, where detectors are implanted in the patient, or
when entrance or exit doses are measured on patient surface).
Therefore, realistic patient treatment plans with measure-
ment data in these phantoms are usually used for final
benchmarking of new algorithms. However, the more com-
plex the phantom, the more challenging it is to perform ac-
curate measurements, especially in 2D or 3D. Thus, the ap-
plication of full MC simulations is a feasible option to com-
prehensive benchmarking.
In the fundamental study by Vassiliev et al.9 the accuracy of
the Acuros algorithm was assessed by applying a breast
treatment plan to an anthropomorphic phantom and com-
paring to full MC simulations. Using 2%/2 mm as acceptance
criteria, the GAI value was 98.7%. Hoffman et al.21 compared
the AXB10 to measured data from an anthropomorphic
thorax phantom with a set of various treatment plans. For 6
and 15 MV beams, with acceptance criteria of 3%/3 mm, the
average GAI values were 98.2% and 99.5%, respectively, all of
them being over 95%. Han et al.43, 44 have studied the accu-
racy of the AXB11 in head & neck (H&N) and lung regions,
using dedicated anthropomorphic phantoms. The comparison
was made against measurements and the AAA for IMRT and
VMAT treatment plans using 6 MV beams. The agreement
between the point dose measurements and the AXB11 were
in ranges from 0.1% to 3.6% and from 0.4% to 4.4% for the
H&N and lung cases, respectively. GAI values of over 90%
and 97% were achieved with acceptance criteria of 5%/3 mm
and ±3%/3 mm for the H&N and lung cases, respectively. The
same dedicated H&N phantom was also used in the work by
Failla et al.4, where the deviations in point doses ranged from
0.5% to 4.6%, averaging to 1.9%. In studies by Kan et al.35, 37,
where the accuracy of the AXB10 for the NPC treatment
planning has been assessed, point and 2D dose distributions
were compared to the AXB10 and the AAA in IMRT treat-
ment plans applied to an anthropomorphic phantom. The
reported discrepancies between the point dose measurements
ranged from 0.7% to 2.6%35 and from 0.0% to 5.5%37, aver-
aging to 1.4% and 1.7%, respectively, while the GAI value
was 91.3% with acceptance criteria of ±3%/3 mm37. In a work
by Ojala et al.3 the accuracy of the AXB10 was benchmarked
in an anthropometric pelvic phantom containing a titanium
alloy implant. By applying a 6 MV beam through the implant
and comparing to measurements and full MC simulations in
MAR-corrected CT dataset, the discrepancies between the
AXB10 (in MAR-corrected CT dataset) and measurements
ranged from -5.5% to 1.8%, averaging to -2.0%, while the
deviations between the full MC simulations and measured
data were from -3.1% to 0.7%, averaging to -0.2%. In addi-
tion, there are two studies, where the primary intention has
not been to benchmark the AXB algorithm, but by including
other calculation methods, a comparison between the meth-
ods can be established. Warren et al.45 studied the optimiza-
tion of collimator margins in lung radiotherapy and used the
AXB10 and the AAA for dose calculation. The improved
accuracy of the AXB10 compared to the AAA resulted to that
in the AXB10 dose distributions the PTV dose coverage was
lower and therefore the effect of the choice of the algorithm
on the subsequent results of the study needs to be assessed. In
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the work by Gimeno et al.46 the AXB10 and the AAA were
used to assess the accuracy of an electronic portal imaging
device (EPID) –based in vivo volumetric dosimetry software,
where the dose calculation was based on pencil beam princi-
ples. The improved accuracy of the AXB10 over the AAA and
pencil beam algorithms revealed larger discrepancies between
the AXB10 and the pencil beam algorithm than between the
AAA and the pencil beam algorithm.
The AXB algorithm and patient plans
The fourth, final step in the validation process of a new dose
calculation algorithm is to quantify how much the dose dis-
tributions of clinical patient plans change, when comparing
to older TPS algorithms. Preferably there should be a com-
parison also to a reference method, which in the case of pa-
tient plans can only be another dose calculation algorithm,
such as full MC simulations.
The largest number of studies in this category is related to the
radiotherapy of the lung, mostly to lung SBRT. In the study
by Bush et al.17 a single 18 MV field was incident on the left
lung and the AXB10 was compared to full MC simulations.
The AXB10 passed the gamma test with ±2%/2 mm ac-
ceptance criteria and the 1.0% to 2.5% differences were par-
tially related to different material assignments between the
calculations. Tsuruta et al.33 benchmarked the AXB11 and the
AAA with XVMC fast MC algorithm in iPlan TPS with lung
SBRT treatment plans. The dose deviations between the
AXB11 and the XVMC algorithm were less than 4% for more
than 94.6% of the points and in dose-volume histogram
(DVH) parameters the differences were less than 2%. Similar
findings were reported by Tomiyama et al.47, who in addition
to the AXB10, the AAA and XVMC fast MC algorithm in
iPlan TPS, also included the PBC algorithm. The discrepan-
cies between the AXB10 and the XVMC algorithm were
within 3%. Chetty et al.48 did not benchmark various dose
calculation algorithms as such in their work, but studied the
correlation of dose distributions with local control in stereo-
tactic ablative radiotherapy (SABR). The included algorithms
were the AXB11, the AAA, XVMC fast MC algorithm in iPlan
TPS, two types of pencil beam algorithms and the CCC algo-
rithm in Pinnacle TPS. The deviations in DVH parameter
values between the AXB11 and the XVMC algorithm were
less than 2.5%. In the study by Stathakis et al.34
jaw-collimated arc plans for lung and paraspinal lesion radi-
otherapy were used to benchmark the AXB10, the AAA and
the CCC algorithm found in Oncentra MasterPlan against full
MC simulations. With all the algorithms the deviations to full
MC simulations ranged from 2% to 5%, the AXB10 being one
of the algorithms with smallest discrepancies. The only study,
where the AXB algorithm has been benchmarked against full
MC simulations in realistic lung SBRT treatment plans is by
Ojala et al.2, where the AXB10, the AAA and the PBC algo-
rithm were compared to each other, accompanied with a
comparison of the AXB10 with full MC simulations. With
3%/3 mm acceptance criteria the 3D GAI values were over
95% for all calculated treatment plans, but stricter criteria,
DVH parameter and dose difference comparison revealed
larger deviations, especially with small isolated target vol-
umes.
Studies, where the AXB algorithm has only been compared to
the AAA, usually through AXB-recalculated AAA treatment
plans, are numerous. Fogliata et al.49 assessed the clinical
impact of the AXB11 in lung radiotherapy by comparing the
dose distributions to the AAA. For the PTV the mean devia-
tions were less than 2% and for the OAR less than 3%. In the
work by Kroon et al.31 the AXB10 was compared to the AAA
in conventional lung radiotherapy and lung SBRT. The larg-
est differences, up to -12.3%, in DVH parameter values were
for the PTV minimum doses, while being less for other DVH
parameters, averaging to the range from -1.8% to 2.0%. In
two studies by Rana et al.40, 41 the AXB10 was compared to the
AAA in lung SBRT for varying-sized PTVs. To the PTV the
AXB10 predicted lower mean and minimum doses (0.3% and
4.3%, respectively40) and higher mean maximum doses (2.3%
40), whereas higher doses to the ipsilateral lung and lower
mean maximum doses to the spinal cord and to the heart. The
more heterogeneous target dose distribution resulting with
the AXB algorithm was also present in the work by Liu
et al.50, where the AXB11 was benchmarked in lung SBRT
with the AAA. The dose heterogeneity also influenced to the
amount of needed monitor units with the AXB11 to deliver
the same prescription dose as with the AAA studied by Khan
et al.51 and to the collimator margin optimization studied by
Warren et al.45.
Kan et al. have studied the dosimetric impact of the AXB
algorithm in the radiotherapy of NPC.35, 36, 37 In the applied
IMRT and VMAT plans originally calculated with the AAA
and recalculated with the AXB10 common findings were that
the AXB10 predicted lower target coverage, lower minimum
target dose, lower mean target dose and also lower doses to
OARs. In breast radiotherapy Fogliata et al.52 compared the
AXB10 and AXB11 to the AAA in a typical two tangential 6
MV field setting. The findings were similar to NPC cases by
Kan et al., i.e., the AXB algorithm predicted lower doses both
to the PTV and to the lung. Interestingly, the paper by
Fogliata et al. is the only study published that reports quan-
titatively the improved calculation accuracy of the AXB11
over the AXB10 in low density materials. Of two other studies
related to breast radiotherapy in the first one by Lonski et al.53
the unknown version of the AXB algorithm was shown to be
superior in out-of-field dose calculation, when comparing to
measurements, the PBC algorithm and the AAA. In the other
study by Petillion et al.54 the choice of dose calculation algo-
rithm was shown to have an impact on the parameters of
radiobiological models. They suggested that the most accurate
solution would be to use the AXB algorithm in Dm,m dose
report mode.
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There are also several reports available on assessing the ac-
curacy of the AXB algorithm on various anatomical regions
and with various clinical diagnoses. Rana et al.55 studied the
clinical impact of the AXB10 over the AAA in prostate cancer
VMAT treatments. In general, the AXB10 predicted lower
dose, but the differences in DVH parameter comparison were
within 1%. In another paper by Rana et al.39 the AXB10 was
benchmarked in the VMAT treatment of esophageal cancer.
In DVH parameter comparison the AXB10 resulted in lower
PTV coverage, lower mean and minimum PTV doses, but
higher maximum PTV dose. Averaged mean doses to all
OARs and maximum doses to heart, liver and spinal cord,
calculated by the AXB10, were lower. The only DVH pa-
rameter value for OARs that was predicted to be higher by
the AXB10 was the maximum lung dose. Fogliata et al.56
performed a dosimetric comparison between the AXB11, the
AAA and proton radiotherapy for soft-tissue sarcoma. No
clear differences were observed in the PTV dose distributions
between the AXB11 and the AAA, though the number of
needed monitor units by the AXB11 was 1.8% higher. Inter-
estingly, the AAA calculation results were closer to the
AXB11 Dm,m calculations than Dw,m calculations, even in the
bone. In a work by Krayenbuehl et al.57 that studied the ap-
plication of IMRT and VMAT for malignant pleural meso-
thelioma the role of the AXB algorithm was limited. Of all the
patient cases only one was calculated with an unknown ver-
sion of the AXB algorithm. The DVH parameter comparison
to the AAA revealed deviations that all were within 1%.
Couple reports include patient plans from multiple anatomi-
cal regions. Kathirvel et al.58 benchmarked the AXB10 and
the AAA against measurement-based CCC calculations. The
treatment plans for lung SBRT and head, H&N, thoracic and
pelvic regions were used for the study. For all the plans the
average difference between the AXB10 and the CCC algo-
rithm were less than 0.5% and GAI values of over 99.5% were
achieved. In the study by Mißlbeck and Kneschaurek22, a
liver, lung SBRT, and H&N patient cases were included to
compare the AXB10 and the AAA to XVMC fast MC algo-
rithm found in iPlan TPS. However, the qualitative analysis
of the DVH data did not reveal such discrepancies between
the algorithms that were anticipated from the results with the
heterogeneous phantom. The first work to include the AXB13
was by Stroom et al.59, who studied the effect of isocenter
positioning in SABR applying VMAT in the brain, lung and
spine. Potentially clinically relevant discrepancies were
found to be involved in the choice of dose calculation algo-
rithm, the AXB11 being preferable. Finally, for the feature
that in the AXB algorithm outperforms other commercially
available algorithms, Lloyd and Ansbacher42 showed that the
dose distribution in the presence of the high-Z hip implant is
much closer to the full MC simulation with the AXB11 than
with the AAA. In Ojala et al.3 the accuracy of the AXB10 was
assessed by replacing the sector of a VMAT arc, from which
the beam would traverse the hip implant and that is normally
planned as an avoidance sector, by three static fields. The
dose distribution was used as base dose plan in VMAT opti-
mization to prepare a clinically acceptable plan. The plan was
recalculated with full MC model and the AAA. The 3D GAI
value between the AXB10 and the full MC simulations was
99.01% and the deviations in the dose distributions in the
vicinity of the implant, but also elsewhere, were small, which
can also be observed in Figure 1 (a)-(b). The differences in
DVH parameters for the PTV were less than 1.5% and less
than 4% in the OARs.
FIG. 1: The isodose curves for a clinical patient plan from Ojala et al.3, calculated both by the AXB algorithm (a) and the MC model (b). Isodose
levels from outermost curve are 10%, 30%, 50%, 70%, 95% and 100% of prescribed dose (PTV white). The constant grey areas represent where
the HU correction is applied.
The AXB algorithm as only dose determination method
On top of all the previously presented studies, in which the
intention has been to assess the accuracy of the AXB algo-
rithm by comparing to reference methods and to reveal the
discrepancies to other commercially available dose calcula-
tion algorithms, there is a number of reports, where the AXB
algorithm has been the only dose determination method used.
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This implies that the authors have had faith in that the algo-
rithm can be applied for reference use and to predict dose
distributions, which are the basis for further research pur-
poses.
Abacioglu et al.60 evaluated the role of VMAT technique for
SRS of benign brain lesions in comparison to Gammaknife
SRS. In the study the AXB10 was the only dose calculation
algorithm for VMAT treatment plans. Fogliata et al.61 and
Mancosu et al.62 have studied the application of VMAT tech-
nique in total marrow irradiation and in the studies, the
AXB10 was the only algorithm that was used. For the radio-
therapy of the breast, another group has produced two papers,
by Essers et al.63 and Osman et al.64, in which the application
of VMAT and breath-hold techniques is assessed applying the
AXB10. Apart from studies with clinical perspectives, Vanetti
et al.65 studied the behavior of two versions of VMAT opti-
mization algorithm implemented in Eclipse TPS and in the
study, the AXB10 was used as the calculation algorithm for
the final dose distributions. Persoon et al.66 applied an un-
known version of the AXB algorithm treatment planning and
predicting the delivered dose from portal dosimetry meas-
urements. Finally, in study by Gersh et al.67, the AXB11 was
used to evaluate the impact of detector choice used in beam
data measurements.
Discussion
Table 1 shows against which dose determination methods the
AXB algorithm has been benchmarked and in what kind of
situations. Studies for each column are needed in the valida-
tion process of a new dose calculation algorithm. Compari-
sons to measurements and full MC simulations are needed,
when the ‘absolute’ accuracy of the new algorithm is deter-
mined. To quantify the difference to existing commercial
algorithms and following clinical impact, comprehensive
benchmarking in various anatomical locations and clinical
settings against other algorithms is required. Table 1 suggests
that the AXB algorithm is comprehensively tested against the
AAA and to some extent against measurements, but more
comparisons against measurements would be beneficial es-
pecially for the AXB11 or the AXB13 in heterogeneous and
more complex phantoms. Since the full MC simulations are
recognized as the gold standard dose determination method,
especially in geometries, where measurements are difficult or
impossible to perform, more studies including full MC simu-
lations are recommended. While the report on differences
between the AXB algorithm and the AAA are numerous,
more data on evaluating the clinical impact of the improved
dose calculation performance in various clinical settings is
needed. Even more beneficial for the radiotherapy commu-
nity would be to include other advanced commercial dose
calculation algorithms, such as fast MC implementations and
the CCC algorithm, to comparisons.
There are no means to provide a simple quantitative descrip-
tion on the accuracy of a dose calculation algorithm. The
reported ‘accuracy’ always depends on, e.g., what is the ref-
erence dose determination method and what is the related
uncertainty, in what kind of phantom/setting the benchmark
is performed and what is the metric used. Therefore it is
always important to explore the original publication carefully
until final conclusions are drawn.
TABLE 1: The distribution of the contents of various studies, including the information on how many times each version of the AXB algorithm is
benchmarked with each type of phantom and against what dose determination method.
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However, from all the covered studies several common
quantitative observations were perceivable. In homogeneous
water phantoms the reported deviations against measure-
ments ranged from 1% to 2% and in areas of high dose gra-
dient, e.g., penumbrae, DTA values of 1 mm were achieved.
These results were for the FSs larger than 2 × 2 cm2, whereas
discrepancies were larger for smaller fields. For the hetero-
geneous phantoms the deviations in lung ranged commonly
from 1% to 3%, being slightly larger for light lung, and up
15% for air. Anyhow, the largest discrepancies occurred
mainly for very limited regions and limited number of
measurements points, usually near the interface. Also, in
these regions the uncertainty of the reference method may be
elevated and the largest reported deviations were for the
AXB10, which has been shown to underperform in certain
circumstances and which has been improved in the AXB11.
With anthropometric and anthropomorphic phantoms the
maximum dose differences against measurements were about
5%, averaging to about 2% or less. For the patient treatment
plan comparisons the relevance of the dose determination
method played a larger role. In general, the reported average
dose differences were up to 3% to 5%, being of similar range
for many DVH parameters and occasionally larger for mini-
mum or maximum dose values, which represent point doses.
Throughout the studies, reported GAI values were generally
high, mostly over 95%, depending on the selected acceptance
criteria.
Conclusions
The number of studies, where the AXB algorithm has been
used, is over 50. Almost without exceptions, the algorithm
has proven to perform better than other existing commercial
dose calculation algorithms. The number of such papers, in
which the AXB algorithm is the only dose determination
method, is already notable, which indicates that the accuracy
of the algorithm is trusted for reference use. This, with re-
ported dosimetric results, implies that the AXB algorithm has
reached its maturity. It has been validated for intended use,
with knowledge on the achievable accuracy. However, there
are situations where the utilization of further verification
methods, such as full MC simulations, is encouraged.
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